Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics

British Journal of Pharmacology

Volumn 172, Issue 1, 2015, Pages 185-200

  Cook, A E ^a   Mistry, S N ^b   Gregory, K J ^a   Furness, S G B ^a   Sexton, P M ^a   Scammells, P J ^b   Conigrave, A D ^c   Christopoulos, A ^a   Leach, K ^a  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZOTHIAZOL 2 YL 1 (2,4 DIMETHYLDIMETHYLPHENYL)ETHANOL; 2 [N [1 [1 NAPHTHYL]ETHYL]AMINOMETHYL]INDOLE; CALCIMIMETIC AGENT; CALCITONIN; CALCIUM SENSING RECEPTOR; CINACALCET; INOSITOL PHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG; [1 [6 METHOXY 4' (TRIFLUOROMETHYL) 3 BIPHENYLYL] N 1 PHENYLETHYL]ETHANAMINE; [3 [2 CHLOROPHENYL] N (1 (3 METHOXYPHENYL)ETHYL) 1 PROPANAMINE]; (R)-2-(1-(1-NAPHTHYL)ETHYL-AMINOM-ETHYL)INDOLE; ANILINE DERIVATIVE; CALCIUM; INDOLE DERIVATIVE; INOSITOL 1-PHOSPHATE; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 3; N-(2-CHLOROPHENYLPROPYL)-1-(3-METHOXYPHENYL)ETHYLAMINE; NAPHTHALENE DERIVATIVE;

ALLOSTERISM; ARTICLE; CALCITONIN BLOOD LEVEL; CALCIUM CELL LEVEL; CALCIUM METABOLISM; CALCIUM MOBILIZATION; CALCIUM SIGNALING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIASTEREOISOMER; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOPLASMIC RETICULUM; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GOLGI COMPLEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPERPARATHYROIDISM; IN VIVO STUDY; LIGAND BINDING; LIPOPHILICITY; PHENOTYPE; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; STIMULUS RESPONSE; SUPERNATANT; AGONISTS; CHEMISTRY; HEK293 CELL LINE; METABOLISM; PHOSPHORYLATION;

ALLOSTERIC REGULATION; ANILINE COMPOUNDS; CALCIMIMETIC AGENTS; CALCIUM; CINACALCET HYDROCHLORIDE; HEK293 CELLS; HUMANS; INDOLES; INOSITOL PHOSPHATES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NAPHTHALENES; PHOSPHORYLATION; RECEPTORS, CALCIUM-SENSING;

EID: 84919629630     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12937     Document Type: Article

References (59)

1. Alam MU, Kirton JP, Wilkinson FL, Towers E, Sinha S, Rouhi M, et al. (2009). Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 81: 260-268.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, et al. (2013a). The concise guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol 170: 1449-1458.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The concise guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
4. Arenas MD, de la Fuente V, Delgado P, Gil MT, Gutierrez P, Ribero J, et al. (2013). Pharmacodynamics of cinacalcet over 48 hours in patients with controlled secondary hyperparathyroidism: useful data in clinical practice. J Clin Endocrinol Metab 98: 1718-1725.
5. Aurelio L, Valant C, Flynn BL, Sexton PM, Christopoulos A, Scammells PJ, (2009). Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. J Med Chem 52: 4543-4547.
6. Avlani VA, Ma W, Mun HC, Leach K, Delbridge L, Christopoulos A, et al. (2013). Calcium-sensing receptor-dependent activation of CREB phosphorylation in HEK-293 cells and human parathyroid cells. Am J Physiol Endocrinol Metab 304: E1097-E1104.
7. Black JW, Leff P, (1983). Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220: 141-162.
8. Broadhead GK, Mun HC, Avlani VA, Jourdon O, Church WB, Christopoulos A, et al. (2011). Allosteric modulation of the calcium-sensing receptor by gamma-glutamyl peptides: inhibition of PTH secretion, suppression of intracellular cAMP levels, and a common mechanism of action with L-amino acids. J Biol Chem 286: 8786-8797.
9. Brown E, Enyedi P, LeBoff M, Rotberg J, Preston J, Chen C, (1987). High extracellular Ca2+ and Mg2+ stimulate accumulation of inositol phosphates in bovine parathyroid cells. FEBS Lett 218: 113-118.
10. Brown EM, (2013). Role of the calcium-sensing receptor in extracellular calcium homeostasis. Best Pract Res Clin Endocrinol Metab 27: 333-343.
11. Cetani F, Picone A, Cerrai P, Vignali E, Borsari S, Pardi E, et al. (2000). Parathyroid expression of calcium-sensing receptor protein and in vivo parathyroid hormone-Ca(2+) set-point in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 85: 4789-4794.
12. Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, et al. (2009). A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 53: 197-207.
13. Christopoulos A, (1998). Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol Sci 19: 351-357.
14. Corbetta S, Lania A, Filopanti M, Vicentini L, Ballare E, Spada A, (2002). Mitogen-activated protein kinase cascade in human normal and tumoral parathyroid cells. J Clin Endocrinol Metab 87: 2201-2205.
15. Davey AE, Leach K, Valant C, Conigrave AD, Sexton PM, Christopoulos A, (2012). Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. Endocrinology 153: 1232-1241.
16. Feng J, Petersen CD, Coy DH, Jiang JK, Thomas CJ, Pollak MR, et al. (2010). Calcium-sensing receptor is a physiologic multimodal chemosensor regulating gastric G-cell growth and gastrin secretion. Proc Natl Acad Sci U S A 107: 17791-17796.
17. Fox J, Lowe SH, Conklin RL, Petty BA, Nemeth EF, (1999a). Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats. J Pharmacol Exp Ther 290: 480-486.
18. Fox J, Lowe SH, Petty BA, Nemeth EF, (1999b). NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 290: 473-479.
19. Freichel M, Zink-Lorenz A, Holloschi A, Hafner M, Flockerzi V, Raue F, (1996). Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribution to calcitonin secretion. Endocrinology 137: 3842-3848.
20. Goolam MA, Ward JH, Avlani VA, Leach K, Christopoulos A, Conigrave AD, (2014). Roles of intraloops-2 and -3 and the proximal C-terminus in signalling pathway selection from the human calcium-sensing receptor. FEBS Lett 588: 3340-3346.
21. Hammerland LG, Garrett JE, Hung BC, Levinthal C, Nemeth EF, (1998). Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 53: 1083-1088.
22. Harrington PE, St Jean DJ Jr, Clarine J, Coulter TS, Croghan M, Davenport A, et al. (2010). The discovery of an orally efficacious positive allosteric modulator of the calcium sensing receptor containing a dibenzylamine core. Bioorg Med Chem Lett 20: 5544-5547.
23. Henley C 3rd, Yang Y, Davis J, Lu JY, Morony S, Fan W, et al. (2011). Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion. J Pharmacol Exp Ther 337: 681-691.
24. Hizaki K, Yamamoto H, Taniguchi H, Adachi Y, Nakazawa M, Tanuma T, et al. (2011). Epigenetic inactivation of calcium-sensing receptor in colorectal carcinogenesis. Mod Pathol 24: 876-884.
25. Kantham L, Quinn SJ, Egbuna OI, Baxi K, Butters R, Pang JL, et al. (2009). The calcium-sensing receptor (CaS receptor) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion. Am J Physiol Endocrinol Metab 297: E915-E923.
26. Kenakin T, (2011). Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336: 296-302.
27. Kenakin T, Christopoulos A, (2013). Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12: 205-216.
28. Kessler A, Faure H, Petrel C, Ruat M, Dauban P, Dodd RH, (2004). N2-benzyl-N1-(1-(1-naphthyl)ethyl)-3-phenylpropane-1,2-diamines and conformationally restrained indole analogues: development of calindol as a new calcimimetic acting at the calcium sensing receptor. Bioorg Med Chem Lett 14: 3345-3349.
29. Kifor O, Moore FD Jr, Wang P, Goldstein M, Vassilev P, Kifor I, et al. (1996). Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81: 1598-1606.
30. Kifor O, Diaz R, Butters R, Brown EM, (1997). The Ca2+-sensing receptor (CaR) activates phospholipases C, A2, and D in bovine parathyroid and CaR-transfected, human embryonic kidney (HEK293) cells. J Bone Miner Res 12: 715-725.
31. Kobayashi M, Tanaka H, Tsuzuki K, Tsuyuki M, Igaki H, Ichinose Y, et al. (1997). Two novel missense mutations in calcium-sensing receptor gene associated with neonatal severe hyperparathyroidism. J Clin Endocrinol Metab 82: 2716-2719.
32. Koole C, Wootten D, Simms J, Valant C, Miller LJ, Christopoulos A, et al. (2011). Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. Mol Pharmacol 80: 486-497.
33. Leach K, Sexton PM, Christopoulos A, (2007). Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28: 382-389.
34. Leach K, Loiacono RE, Felder CC, McKinzie DL, Mogg A, Shaw DB, et al. (2010). Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35: 855-869.
35. Leach K, Wen A, Davey AE, Sexton PM, Conigrave AD, Christopoulos A, (2012). Identification of molecular phenotypes and biased signaling induced by naturally occurring mutations of the human calcium-sensing receptor. Endocrinology 153: 4304-4316.
36. Leach K, Wen A, Cook AE, Sexton PM, Conigrave AD, Christopoulos A, (2013). Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators. Endocrinology 154: 1105-1116.
37. Leach K, Sexton PM, Christopoulos A, Conigrave AD, (2014). Engendering biased signalling from the calcium-sensing receptor for the pharmacotherapy of diverse disorders. Br J Pharmacol 171: 1142-1155.
38. Liu KP, Russo AF, Hsiung SC, Adlersberg M, Franke TF, Gershon MD, et al. (2003). Calcium receptor-induced serotonin secretion by parafollicular cells: role of phosphatidylinositol 3-kinase-dependent signal transduction pathways. J Neurosci 23: 2049-2057.
39. Loupy A, Ramakrishnan SK, Wootla B, Chambrey R, de la Faille R, Bourgeois S, et al. (2012). PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor. J Clin Invest 122: 3355-3367.
40. Ma JN, Owens M, Gustafsson M, Jensen J, Tabatabaei A, Schmelzer K, et al. (2011). Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor. J Pharmacol Exp Ther 337: 275-284.
41. Mace OJ, Schindler M, Patel S, (2012). The regulation of K- and L-cell activity by GLUT2 and the calcium-sensing receptor CaS receptor in rat small intestine. J Physiol 590: 2917-2936.
42. Macleod RJ, (2013). CaS receptor function in the intestine: hormone secretion, electrolyte absorption and secretion, paracrine non-canonical Wnt signaling and colonic crypt cell proliferation. Best Pract Res Clin Endocrinol Metab 27: 385-402.
43. Makita N, Sato J, Manaka K, Shoji Y, Oishi A, Hashimoto M, et al. (2007). An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations. Proc Natl Acad Sci U S A 104: 5443-5448.
44. Mamillapalli R, VanHouten J, Zawalich W, Wysolmerski J, (2008). Switching of G-protein usage by the calcium-sensing receptor reverses its effect on parathyroid hormone-related protein secretion in normal versus malignant breast cells. J Biol Chem 283: 24435-24447.
45. Marie PJ, (2010). The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone 46: 571-576.
46. McGehee DS, Aldersberg M, Liu KP, Hsuing S, Heath MJ, Tamir H, (1997). Mechanism of extracellular Ca2+ receptor-stimulated hormone release from sheep thyroid parafollicular cells. J Physiol 502: 31-44.
47. Mun HC, Brennan SC, Delbridge L, Wilkinson M, Brown EM, Conigrave AD, (2009). Adenomatous human parathyroid cells exhibit impaired sensitivity to L-amino acids. J Clin Endocrinol Metab 94: 3567-3574.
48. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, et al. (1998). Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 95: 4040-4045.
49. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, et al. (2004). Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308: 627-635.
50. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
51. Quinn SJ, Kifor O, Kifor I, Butters RR Jr, Brown EM, (2007). Role of the cytoskeleton in extracellular calcium-regulated PTH release. Biochem Biophys Res Commun 354: 8-13.
52. Rey O, Young SH, Yuan J, Slice L, Rozengurt E, (2005). Amino acid-stimulated Ca2+ oscillations produced by the Ca2+-sensing receptor are mediated by a phospholipase C/inositol 1,4,5-trisphosphate-independent pathway that requires G12, Rho, filamin-A, and the actin cytoskeleton. J Biol Chem 280: 22875-22882.
53. Rey O, Young SH, Jacamo R, Moyer MP, Rozengurt E, (2010). Extracellular calcium sensing receptor stimulation in human colonic epithelial cells induces intracellular calcium oscillations and proliferation inhibition. J Cell Physiol 225: 73-83.
54. Russell J, Zhao W, Christ G, Ashok S, Angeletti RH, (1999). Ca2+-induced increases in steady-state concentrations of intracellular calcium are not required for inhibition of parathyroid hormone secretion. Mol Cell Biol Res Commun 1: 221-226.
55. Singh N, Liu G, Chakrabarty S, (2012). Isolation and characterization of calcium sensing receptor null cells: a highly malignant and drug resistant phenotype of colon cancer. Int J Cancer 132: 1996-2005.
56. Smajilovic S, Yano S, Jabbari R, Tfelt-Hansen J, (2011). The calcium-sensing receptor and calcimimetics in blood pressure modulation. Br J Pharmacol 164: 884-893.
57. Thomsen AR, Hvidtfeldt M, Brauner-Osborne H, (2012a). Biased agonism of the calcium-sensing receptor. Cell Calcium 51: 107-116.
58. Thomsen AR, Worm J, Jacobsen SE, Stahlhut M, Latta M, Brauner-Osborne H, (2012b). Strontium is a biased agonist of the calcium-sensing receptor in rat medullary thyroid carcinoma 6-23 cells. J Pharmacol Exp Ther 343: 638-649.
59. Yano S, Sugimoto T, Tsukamoto T, Chihara K, Kobayashi A, Kitazawa S, et al. (2000). Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int 58: 1980-1986.